Additionally, the 36-month beta value for DRIO is 1.39. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The average price predicted by analysts for DRIO is $3.88, which is $2.69 above the current price. The public float for DRIO is 24.07M and currently, short sellers hold a 5.78% ratio of that float. The average trading volume of DRIO on November 20, 2023 was 172.54K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


DRIO) stock’s latest price update

The stock price of DarioHealth Corp (NASDAQ: DRIO) has jumped by 17.82 compared to previous close of 1.01. Despite this, the company has seen a gain of 11.21% in its stock price over the last five trading days. Seeking Alpha reported 2023-10-03 that DarioHealth has experienced a disappointing year with stalled revenue growth and a decline in new customer wins. However, H2/23 and FY24 are expected to bring improved financials, including revenue growth, expanded gross margins, and declining operating expenses. The company’s competitive advantages include a customer-friendly platform, a multi-condition platform, and partnerships with important industry players.

DRIO’s Market Performance

DRIO’s stock has risen by 11.21% in the past week, with a monthly drop of -56.41% and a quarterly drop of -56.25%. The volatility ratio for the week is 10.79% while the volatility levels for the last 30 days are 17.97% for DarioHealth Corp The simple moving average for the past 20 days is -12.48% for DRIO’s stock, with a -66.29% simple moving average for the past 200 days.

Analysts’ Opinion of DRIO

Many brokerage firms have already submitted their reports for DRIO stocks, with Alliance Global Partners repeating the rating for DRIO by listing it as a “Buy.” The predicted price for DRIO in the upcoming period, according to Alliance Global Partners is $8.75 based on the research report published on May 13, 2022 of the previous year 2022.

DRIO Trading at -49.54% from the 50-Day Moving Average

After a stumble in the market that brought DRIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.45% of loss for the given period.

Volatility was left at 17.97%, however, over the last 30 days, the volatility rate increased by 10.79%, as shares sank -52.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.47% lower at present.

During the last 5 trading sessions, DRIO rose by +11.21%, which changed the moving average for the period of 200-days by -77.72% in comparison to the 20-day moving average, which settled at $1.2938. In addition, DarioHealth Corp saw -72.20% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at DRIO starting from Raphael Erez, who sale 1,200 shares at the price of $6.21 back on Jan 13. After this action, Raphael Erez now owns 1,112,059 shares of DarioHealth Corp, valued at $7,449 using the latest closing price.

MCGRATH DENNIS M, the Director of DarioHealth Corp, sale 9,872 shares at $3.97 during a trade that took place back on Dec 21, which means that MCGRATH DENNIS M is holding 74,744 shares at $39,206 based on the most recent closing price.

Stock Fundamentals for DRIO

Current profitability levels for the company are sitting at:

The net margin for DarioHealth Corp stands at -216.80. The total capital return value is set at -59.12, while invested capital returns managed to touch -64.99. Equity return is now at value -72.09, with -48.60 for asset returns.

Based on DarioHealth Corp (DRIO), the company’s capital structure generated 35.06 points at debt to equity in total, while total debt to capital is 25.96. Total debt to assets is 23.53, with long-term debt to equity ratio resting at 23.67. Finally, the long-term debt to capital ratio is 17.52.

When we switch over and look at the enterprise to sales, we see a ratio of 0.46, with the company’s debt to enterprise value settled at 0.35. The receivables turnover for the company is 6.55 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.36.


In conclusion, DarioHealth Corp (DRIO) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.